Switch theme
Sign up to access all valuation multiples
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
1999
299
LTM Revenue $0.2M
LTM EBITDA -$250M
-$22.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Rocket Pharmaceuticals has a last 12-month revenue (LTM) of $0.2M and a last 12-month EBITDA of -$250M.
In the most recent fiscal year, Rocket Pharmaceuticals achieved revenue of n/a and an EBITDA of -$247M.
Rocket Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Rocket Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.2M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | -$0.7M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | -315% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$250M | XXX | -$247M | XXX | XXX | XXX |
| EBITDA Margin | -117662% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$266M | XXX | -$273M | XXX | XXX | XXX |
| EBIT Margin | -125393% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$252M | XXX | -$259M | XXX | XXX | XXX |
| Net Margin | -118650% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Rocket Pharmaceuticals's stock price is $3.
Rocket Pharmaceuticals has current market cap of $270M, and EV of -$22.4M.
See Rocket Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$22.4M | $270M | XXX | XXX | XXX | XXX | $-2.52 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Rocket Pharmaceuticals has market cap of $270M and EV of -$22.4M.
Rocket Pharmaceuticals's trades at n/a EV/Revenue multiple, and 0.1x EV/EBITDA.
Equity research analysts estimate Rocket Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Rocket Pharmaceuticals has a P/E ratio of -1.1x.
See valuation multiples for Rocket Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $270M | XXX | $270M | XXX | XXX | XXX |
| EV (current) | -$22.4M | XXX | -$22.4M | XXX | XXX | XXX |
| EV/Revenue | -105.4x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/EBIT | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/Gross Profit | 33.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.1x | XXX | -1.0x | XXX | XXX | XXX |
| EV/FCF | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRocket Pharmaceuticals's last 12 month revenue growth is 17392%
Rocket Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.9M for the same period.
Rocket Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Rocket Pharmaceuticals's rule of X is -74181% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Rocket Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 17392% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -117662% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -22% | XXX | 4% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -74181% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Rocket Pharmaceuticals acquired XXX companies to date.
Last acquisition by Rocket Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Rocket Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Rocket Pharmaceuticals founded? | Rocket Pharmaceuticals was founded in 1999. |
| Where is Rocket Pharmaceuticals headquartered? | Rocket Pharmaceuticals is headquartered in United States of America. |
| How many employees does Rocket Pharmaceuticals have? | As of today, Rocket Pharmaceuticals has 299 employees. |
| Who is the CEO of Rocket Pharmaceuticals? | Rocket Pharmaceuticals's CEO is Dr. Gaurav Shah, M.D.. |
| Is Rocket Pharmaceuticals publicy listed? | Yes, Rocket Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Rocket Pharmaceuticals? | Rocket Pharmaceuticals trades under RCKT ticker. |
| When did Rocket Pharmaceuticals go public? | Rocket Pharmaceuticals went public in 2015. |
| Who are competitors of Rocket Pharmaceuticals? | Similar companies to Rocket Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Rocket Pharmaceuticals? | Rocket Pharmaceuticals's current market cap is $270M |
| What is the current revenue of Rocket Pharmaceuticals? | Rocket Pharmaceuticals's last 12 months revenue is $0.2M. |
| What is the current revenue growth of Rocket Pharmaceuticals? | Rocket Pharmaceuticals revenue growth (NTM/LTM) is 17392%. |
| What is the current EV/Revenue multiple of Rocket Pharmaceuticals? | Current revenue multiple of Rocket Pharmaceuticals is -105.4x. |
| Is Rocket Pharmaceuticals profitable? | Yes, Rocket Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Rocket Pharmaceuticals? | Rocket Pharmaceuticals's last 12 months EBITDA is -$250M. |
| What is Rocket Pharmaceuticals's EBITDA margin? | Rocket Pharmaceuticals's last 12 months EBITDA margin is -117662%. |
| What is the current EV/EBITDA multiple of Rocket Pharmaceuticals? | Current EBITDA multiple of Rocket Pharmaceuticals is 0.1x. |
| What is the current FCF of Rocket Pharmaceuticals? | Rocket Pharmaceuticals's last 12 months FCF is -$205M. |
| What is Rocket Pharmaceuticals's FCF margin? | Rocket Pharmaceuticals's last 12 months FCF margin is -96549%. |
| What is the current EV/FCF multiple of Rocket Pharmaceuticals? | Current FCF multiple of Rocket Pharmaceuticals is 0.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
